Search
Glaukos Corp
GKOSAdd to Watchlist
153.580USD
+1.525+1.00%
Close 07-24 16:00（ET）Quotes delayed by 15 min
8.83BMarket Cap
LossP/E TTM
More Details of Glaukos Corp Company
Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; and bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders, such as keratoconus or refractive disorders, among others.
Glaukos Corp Info
Ticker SymbolGKOS
Company nameGlaukos Corp
IPO dateJun 25, 2015
CEOBurns (Thomas William)
Number of employees995
Security typeOrdinary Share
Fiscal year-endJun 25
Address1 Glaukos Way
CityALISO VIEJO
Stock exchangeNASDAQ OMX NASDAQ Basic NYSE
CountryUnited States of America
Postal code92656
Phone19493679600
Websitehttps://www.glaukos.com
Ticker SymbolGKOS
IPO dateJun 25, 2015
CEOBurns (Thomas William)
Company Executives of Glaukos Corp
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas William Burns
Mr. Thomas William Burns
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.70M
-0.24%
Mr. David F. Hoffmeister
Mr. David F. Hoffmeister
Independent Director
Independent Director
86.97K
+19.41%
Mr. Mark J. Foley
Mr. Mark J. Foley
Lead Independent Director
Lead Independent Director
59.10K
+3.18%
Ms. Aimee S. Weisner, J.D.
Ms. Aimee S. Weisner, J.D.
Independent Director
Independent Director
51.57K
+3.64%
Dr. Tomas Navratil
Dr. Tomas Navratil
Chief Development Officer
Chief Development Officer
47.84K
-1.50%
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Independent Director
Independent Director
38.60K
+4.87%
Dr. Gilbert H. (Gil) Kliman, M.D.
Dr. Gilbert H. (Gil) Kliman, M.D.
Independent Director
Independent Director
--
--
Mr. Joseph E. Gilliam
Mr. Joseph E. Gilliam
President, Chief Operating Officer
President, Chief Operating Officer
--
--
Dr. Leana S. Wen, M.D.
Dr. Leana S. Wen, M.D.
Independent Director
Independent Director
--
--
Ms. Denice M. Torres, J.D.
Ms. Denice M. Torres, J.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Thomas William Burns
Mr. Thomas William Burns
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
1.70M
-0.24%
Mr. David F. Hoffmeister
Mr. David F. Hoffmeister
Independent Director
Independent Director
86.97K
+19.41%
Mr. Mark J. Foley
Mr. Mark J. Foley
Lead Independent Director
Lead Independent Director
59.10K
+3.18%
Ms. Aimee S. Weisner, J.D.
Ms. Aimee S. Weisner, J.D.
Independent Director
Independent Director
51.57K
+3.64%
Dr. Tomas Navratil
Dr. Tomas Navratil
Chief Development Officer
Chief Development Officer
47.84K
-1.50%
Mr. Marc A. Stapley
Mr. Marc A. Stapley
Independent Director
Independent Director
38.60K
+4.87%
FAQs
Who are the top five shareholders of Glaukos Corp?
The top five shareholders of Glaukos Corp are: Mr. Thomas William Burns
How many institutions hold shares of Glaukos Corp (GKOS)?
As of 2026Q1, 702 institutions hold shares of Glaukos Corp, with a combined market value of approximately 59.35M, accounting for 101.04% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -2784097.00.
What is the biggest source of revenue for Glaukos Corp?
In 2026Q1, the Glaucoma business generated the highest revenue for Glaukos Corp, amounting to 421.07M and accounting for 82.98% of total revenue.